Browse the evidence

A 3-month intervention combining alternate day fasting (600 kcal on fast days) and moderate-intensity aerobic exercise significantly reduces intrahepatic triglyceride content and associated cardiometabolic risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).

For patients with fatty liver disease, a 3-month program of Alternate Day Fasting (eating 600 calories on fast days, normal on others) combined with 5 weekly sessions of moderate exercise (like brisk walking or cycling) significantly reduces liver fat. This approach is a validated, mainstay therapy that works by creating a caloric deficit and improving metabolic markers, even without drastic daily calorie counting.

High-intensity behavioral interventions involving at least 14 sessions over six months produce significant weight loss (5-10%) and improve glycemic control.

Structured behavioral programs are highly effective for weight loss, especially for those with type 2 diabetes. Committing to at least 14 sessions over six months can lead to a 5-10% reduction in body weight. These programs use techniques like self-monitoring and goal setting to improve adherence and health outcomes.

Semaglutide demonstrates the greatest mean reduction in body weight among GLP-1RAs in psychiatric populations, significantly outperforming placebo and showing superior efficacy to liraglutide and exenatide in network meta-analysis.

Among GLP-1 medications, semaglutide (oral) appears to produce the most significant weight loss in patients with psychiatric conditions, averaging over 6 kg (13 lbs) loss. It is more effective than liraglutide or exenatide in this group. However, data is limited to one study, so discuss availability and cost with your provider.

Intentional weight loss of 10% or more significantly improves cardiovascular outcomes, including arrhythmic free survival and symptom severity in atrial fibrillation, whereas lesser degrees of weight loss (e.g., 5%) do not show the same benefit.

If you have Atrial Fibrillation and are overweight, aim for a weight loss of at least 10% of your body weight. Small losses (like 5%) may not be enough to significantly improve your heart rhythm or symptoms. Consult your doctor for a structured weight loss plan.

Dual GLP-1R/GIPR agonists (e.g., tirzepatide) provide superior glycemic control and weight reduction compared to single-target incretin agonists.

If you have type 2 diabetes or obesity, dual-acting medications like tirzepatide may offer better weight loss and blood sugar control than older single-acting drugs. These are injectable medications that mimic gut hormones to reduce appetite and improve insulin function. Consult a doctor to see if this advanced therapy is appropriate for your specific health profile.

Weight loss of 7-10% of body weight improves the majority of histopathological features of NASH, including fibrosis, achieved through a daily calorie reduction of 500-1000 kcal combined with moderate-intensity exercise.

To improve liver health in NASH, aim to lose 7-10% of your body weight. This is best achieved by eating 500-1000 fewer calories per day and exercising moderately for 150 minutes a week. Even a 3-5% loss helps with liver fat, but the higher target is needed to reverse fibrosis.

Regular moderate exercise (150 minutes/week) provides hepatic and cardiometabolic benefits independent of weight loss.

Aim for 150 minutes of moderate exercise per week (e.g., brisk walking). This helps your liver and heart health directly, even if you don't lose weight.

Adherence to a Mediterranean diet, characterized by high intake of olive oil, vegetables, fruits, nuts, legumes, whole grains, fish, and seafood, with low intake of red and processed meat and reduced carbohydrates, offers cardiovascular benefits and is recommended for NAFLD management.

Eat a Mediterranean-style diet: lots of vegetables, fruits, nuts, legumes, whole grains, fish, and olive oil. Limit red and processed meat and keep carbohydrates to about 40% of your calories.

Protein supplementation combined with resistance training is the most prominent and effective intervention strategy for promoting muscle hypertrophy.

To maximize muscle growth, combine regular resistance training with adequate protein intake. This combination is the most widely supported strategy in current research. Ensure your training is progressive, as protein alone is not enough to overcome adaptation plateaus.

Supplementing pea protein with Lactiplantibacillus plantarum TWK10 (1x10^10 CFU) significantly increases the absorption of branched-chain, essential, and total amino acids compared to pea protein alone, leading to greater improvements in muscle thickness, strength, and anaerobic power in healthy adults undergoing resistance training.

If you are using pea protein for muscle building, adding Lactiplantibacillus plantarum TWK10 (10 billion CFU) to your daily 20g dose may significantly boost your muscle growth and strength gains. Take the mixture 30 minutes after resistance training or before bed for 4 weeks. This is particularly useful if you are vegetarian or vegan and want to maximize the benefits of plant-based protein.

Collagen supplementation significantly enhances fat-free mass and muscle strength gains in healthy adults undergoing resistance training, outperforming whey protein and other protein sources.

If you are doing resistance training, adding collagen supplements can significantly boost your muscle mass and strength gains, potentially more than whey protein. You don't need to rely solely on high-BCAA proteins; collagen's unique amino acids support muscle structure and recovery. Aim for a daily dose that fits your diet, as the study shows benefits across various dosages.

Whey protein supplementation significantly enhances muscle strength and fat-free mass gains compared to placebo, but is less effective than collagen.

Whey protein works for building muscle and strength, but the gains are smaller than those from collagen. If you are using whey, consider adding collagen to your regimen for potentially better results. Don't rely on whey alone if you want to maximize your strength and mass gains.

Intensive lifestyle interventions combining caloric restriction and moderate-intensity physical activity significantly reduce Obstructive Sleep Apnea (OSA) severity and can lead to remission in overweight or obese adults, with a linear dose-response relationship between weight loss magnitude and improvement in Apnea-Hypopnea Index (AHI).

If you have OSA and are overweight, losing weight is the most effective way to reduce its severity. Aim for a sustained weight loss of 10% or more through a combination of a reduced-calorie diet (1200-1800 kcal/day) and at least 175 minutes of moderate exercise per week. While CPAP is important, it doesn't fix the underlying obesity; combining it with these lifestyle changes offers the best chance for remission and long-term health.

Replacing processed animal meats with plant-based meat analogues (PBMAs) significantly reduces saturated fat and total energy intake while increasing dietary fiber, leading to more favorable Nutri-Score ratings in most categories.

Switching from processed animal meats (like sausages and bacon) to plant-based analogues generally lowers your saturated fat and calorie intake while boosting fiber. However, check the label: many analogues are high in salt and sugar, and few are fortified with B12 or Iron. Choose products with lower sodium and consider a B12 supplement if you rely heavily on these substitutes.

High early engagement with a commercial weight-loss program (defined as meeting weekly coach call and daily website login goals within the first 3 months) significantly increases the odds of long-term retention (6 and 12 months).

To stay in a commercial weight-loss program, focus heavily on the first three months. Make sure you are completing all scheduled coach calls and logging into the website daily. This early engagement is the strongest predictor of whether you will stick with the program long-term.

Achieving early weight-loss success (≥5% loss at 6 months) significantly increases the odds of long-term retention, while early weight-loss failure (≥0% change at 1 month) significantly decreases it.

If you don't see weight loss in the first month, you are at high risk of dropping out. Programs should identify these individuals early and provide extra support to help them get back on track, as early failure is a strong predictor of quitting.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce clinically significant weight loss (15-21%) and improve comorbidities, but require long-term continuous use to maintain benefits.

GLP-1 medications like semaglutide and tirzepatide are highly effective for significant weight loss (15-21%) and improving health conditions like diabetes and heart disease. However, they are not cosmetic shortcuts. You must commit to long-term use, as stopping the medication usually leads to regaining the weight. Work with your doctor to manage side effects and adjust other medications as you lose weight.

GLP-1/GIP dual receptor agonists (e.g., tirzepatide) produce significantly greater weight loss than GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and non-GLP-1 agents (e.g., orlistat, phentermine/topiramate) in weight management trials.

If you are struggling with obesity, GLP-1/GIP dual agonists like tirzepatide are currently the most effective pharmacological option for weight loss, significantly outperforming older medications and even single-target GLP-1 agonists. This comes with the need for weekly injections (or oral alternatives) and careful dose escalation to manage side effects.

GLP-1 receptor agonists (semaglutide 2.4 mg weekly) and dual incretin agonists (tirzepatide) significantly reduce hepatic steatosis and improve or resolve steatohepatitis (MASH) in patients with MASLD, primarily through sustained weight loss and improved insulin sensitivity.

If you have fatty liver disease linked to metabolic issues, GLP-1 medications like semaglutide are currently the most effective pharmacological tool to reverse liver inflammation and fat. They work by targeting the root metabolic causes rather than just the liver itself. Consult a doctor to see if you qualify for these treatments, especially if lifestyle changes alone haven't resolved your liver health markers.

Intensive lifestyle interventions (dietary restriction and exercise) can induce type 2 diabetes remission, with remission rates strongly dose-dependent on the magnitude of weight loss, particularly when exceeding 15 kg.

To achieve type 2 diabetes remission, you must lose a significant amount of weight, ideally 15 kg or more, through a combination of calorie-restricted diet and regular exercise (at least 150 minutes/week). This is not just about weight loss; it requires a multidisciplinary support system including dietitians and psychological counseling to manage the mental burden of strict lifestyle changes. Shorter diabetes duration and higher BMI (27-45) predict better success.

A worksite-based behavioral intervention emphasizing hunger and craving management via diet composition produces significant, sustained weight loss (approx. 9%) and improvements in cardiometabolic risk factors (glucose, triglycerides) over 18 months, regardless of whether meal replacements are used.

Adopt a behavioral program that focuses on managing hunger and cravings through diet composition rather than just calorie counting. This approach can lead to significant, sustained weight loss (around 9%) and improved heart health markers over 18 months. You do not necessarily need meal replacements to lose weight, though they may help lower cholesterol further. The key is a low-burden, sustainable behavioral change.

Tirzepatide, a dual GLP-1/GIP receptor agonist, provides greater HbA1c reduction and weight loss compared to semaglutide 1 mg in patients with Type 2 Diabetes.

If you need significant weight loss and blood sugar control, ask your doctor about tirzepatide. It may work better than older GLP-1 drugs like semaglutide 1 mg, but it is more expensive.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce significant weight loss (10-21%) but also reduce lean body mass, necessitating resistance training to preserve muscle and performance in physically active individuals.

If you are using GLP-1 agonists like semaglutide or tirzepatide for weight loss, expect to lose both fat and some muscle. To protect your strength and athletic performance, you must incorporate resistance training into your routine. This combination helps offset the lean mass loss associated with these drugs. Do not rely on the medication alone; long-term maintenance requires continuous therapy and lifestyle adherence, as stopping treatment typically leads to weight regain.

Semaglutide (2.4 mg) is the most cost-effective and clinically effective pharmacological intervention for obesity treatment compared to other FDA-approved medications and lifestyle interventions.

For adults with obesity, Semaglutide (2.4 mg weekly) combined with diet and exercise is currently the most effective and economically favorable medication option available, outperforming older drugs like Orlistat in most healthcare settings.